Short Interest in Biopharmx Corp (BPMX) Expands By 16.2%

Biopharmx Corp (NYSEAMERICAN:BPMX) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 12,130,469 shares, a growth of 16.2% from the February 28th total of 10,443,253 shares. Currently, 11.7% of the shares of the stock are short sold. Based on an average trading volume of 25,386,385 shares, the short-interest ratio is presently 0.5 days.

In other news, major shareholder Vivo Capital Viii, Llc sold 2,000,000 shares of the stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $0.36, for a total value of $720,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

How to Become a New Pot Stock Millionaire

A hedge fund recently bought a new stake in Biopharmx stock. Sabby Management LLC acquired a new stake in Biopharmx Corp (NYSEAMERICAN:BPMX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,713,756 shares of the biotechnology company’s stock, valued at approximately $740,000. Sabby Management LLC owned 5.27% of Biopharmx as of its most recent SEC filing.

Separately, Maxim Group restated a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a report on Friday, December 8th.

Biopharmx (NYSEAMERICAN:BPMX) remained flat at $$0.28 during midday trading on Monday. 6,664,117 shares of the company’s stock were exchanged, compared to its average volume of 15,995,425. The firm has a market capitalization of $45.42, a price-to-earnings ratio of -1.04 and a beta of 0.43. Biopharmx has a one year low of $0.10 and a one year high of $0.90.

TRADEMARK VIOLATION NOTICE: “Short Interest in Biopharmx Corp (BPMX) Expands By 16.2%” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3303074/short-interest-in-biopharmx-corp-bpmx-expands-by-16-2.html.

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Intuit  Reaches New 1-Year High and Low at $182.93
Intuit Reaches New 1-Year High and Low at $182.93
Mitel Networks  Hits New 12-Month High and Low at $11.31
Mitel Networks Hits New 12-Month High and Low at $11.31
SodaStream  Reaches New 12-Month High and Low at $98.26
SodaStream Reaches New 12-Month High and Low at $98.26
$262.66 Million in Sales Expected for Voya Financial  This Quarter
$262.66 Million in Sales Expected for Voya Financial This Quarter
Zacks: Analysts Expect ICF  Will Post Quarterly Sales of $304.14 Million
Zacks: Analysts Expect ICF Will Post Quarterly Sales of $304.14 Million
American Ecology Co.  Expected to Post Quarterly Sales of $114.50 Million
American Ecology Co. Expected to Post Quarterly Sales of $114.50 Million


© 2006-2018 Ticker Report. Google+.